Research ethics during a pandemic (COVID-19)

Kheng-Wei Yeoh\textsuperscript{a,*} and Ketan Shah\textsuperscript{b}

\textsuperscript{a}Singapore General Hospital, SingHealth, Singapore 169608; \textsuperscript{b}Oxford University Hospitals NHS Trust, Old Road, Oxford OX3 7SG, UK

\textsuperscript{*}Corresponding author: Tel: +65 64368000; Fax: +65 62228675; E-mail: yeoh.khengwei@sg.h.com.sg

Received 15 May 2020; revised 20 July 2020; editorial decision 5 August 2020; accepted 8 September 2020

Keywords: Medical Ethics, International Health, COVID-19 Pandemic.

The current pandemic with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in a major global health crisis.\textsuperscript{1} This has put tremendous strain on healthcare systems around the world and naturally raises issues concerning the allocation of scarce resources. It presents a clear and urgent need for research into management of the disease in individuals and of the epidemic in populations. Addressing this need around the world raises practical and ethical issues for the scientific research community internationally.

There have been several recommendations addressing ethical issues which arise during global health emergencies, including the current COVID-19 pandemic.\textsuperscript{2-4} These partly serve to set guidance based on distributive justice to allocate limited healthcare resources appropriately, and have been based on the relevant ethical principles of justice, beneficence, utility, respect for persons, liberty, reciprocity and solidarity. With regards to fair allocation of scarce resources during the COVID-19 outbreak, recommendations have been made in line with the utilitarian approach of maximising benefits and are based on four guiding principles: (1) maximising total benefits produced by scarce resources, (2) treating equivalent cases equally, (3) promoting and rewarding instrumental value (benefit to others) and (4) giving priority to the worst off.\textsuperscript{5}

More practical guidelines relating to critical care access have been set based on urgency of medical need, the likelihood and duration of clinical benefit and the change in quality of life.\textsuperscript{6} Algorithms have been adopted to maximise patient safety and to direct the appropriate use of resources in the event that they become scarce.\textsuperscript{7}

Recommendations have also been set to prioritise research in COVID-19-related work with immediate and mid- to long-term priorities.\textsuperscript{3,4} The immediate aims focus on accelerating research that can contribute to containing the spread of this epidemic and helping those affected to receive optimal care. The mid- to long-term priorities stemming from experience of this pandemic are to develop global research platforms aiding preparedness for the next unforeseen epidemic and to encourage research, development and equitable access, based on public health needs, to diagnostics, therapeutics and vaccines.\textsuperscript{4} The process of prioritisation to meet the above needs will result in reallocating staff and resources towards COVID-19-related activities, which will naturally have its pros and cons. The imperative for research must therefore be balanced by the need to avoid unduly diverting resources, including personnel, equipment and healthcare facilities, from other critical clinical and public health efforts.\textsuperscript{7} Emphasis must also be put on the need to coordinate research within and between research institutions as well as with government bodies to avoid overlapping protocols amidst changing standards of care, which is particularly pertinent in settings where resources are limited.

Despite the pressures that typically surround pandemics to implement treatments with a promising rationale directly including research invitations, the research community should assert the benefits of testing treatment hypotheses with methodological rigour.\textsuperscript{3} This approach has arguably led to reliable improvements in treatment, for example, demonstrating the ineffectiveness of hydroxychloroquine and benefits of dexamethasone for patients with COVID-19.\textsuperscript{9,10} While the investigators have used established methods such as randomised controlled trials, they have chosen to expedite publication of the results before traditional peer review, using press releases and preprint archives such as bioRxiv and medRxiv.

Many of the issues mentioned above will affect institutional review and medical ethics boards (IRBs) and research ethics committees (RECs) around the world as they continue to administer research governance during the health emergency. The majority of guidance for IRBs during the COVID-19 pandemic have focused on the logistics of clinical trials, with less focus on new study submissions during this outbreak.\textsuperscript{11,12} IRBs and RECs are faced with prioritising new study submissions and modifying ongoing research activity while staying true to the ethical principles and international guidance discussed above.

We therefore propose recommendations to guide research governance during the COVID-19 pandemic:

© The Author(s) 2020. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
(1) Review of new research study submissions may be expedited, but not compromised in quality, particularly in relation to fair consent, the safety of study participants and ensuring methodological validity to answer the scientific question asked. Scrutiny should be applied to the publication strategy emphasising good publishing practice, with the need for data transparency and peer review balanced against the benefit of expediting knowledge of study results in a rapidly developing pandemic.

(2) Research methodology should be assessed in the context of potentially stretched clinical resources. The best designs will be conducive to the delivery of direct clinical care and good designs will be complementary. Research that competes for resources such as staff, protective equipment and hospital capacity should be carefully assessed as described above, but may be justified in the immediate term to help contain the pandemic and to help those affected to receive optimal care, for example, in the testing of novel treatment and vaccines.

(3) As the coronavirus pandemic develops, COVID-19 will come to sit among other medical conditions in the clinical landscape. COVID-19-related research should be considered alongside research into other conditions and evaluated on the same terms. In the short term, research into COVID-19 is likely to be prioritised due to its clinical urgency and the imperative to study the ongoing pandemic as it develops.

(4) Research that was planned or ongoing before the pandemic may need to be reassessed and formally reviewed, for example, in relation to risks to study participants, particularly the impact on patients who are already suffering from life-threatening and, in some settings, highly stigmatised disease, or to comply with public health control measures such as social distancing requirements.

Authors’ contributions: The authors contributed to all aspects of the article.

Funding: None.

Competing interests: None declared.

Ethical approval: Not required.

References
1. Coronavirus disease (COVID-19) pandemic. World Health Organization. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [accessed July 18, 2020].
2. Guidance for Managing Ethical Issues in Infectious Disease Outbreaks. World Health Organization, 2016.
3. Research in Global Health Emergencies: Ethical Issues. Nuffield Council on Bioethics, 2020.
4. Ethical standards for research during public health emergencies: Distilling existing guidance to support COVID-19 R&D. World Health Organization. 2020. https://apps.who.int/iris/bitstream/handle/10665/331507/WHO-RFH-20.1-eng.pdf?sequence=1&isAllowed=y [accessed May 7, 2020].
5. Emanuel EJ, Persad G, Upshur R, et al. Fair allocation of scarce medical resources in the time of COVID-19. NEJM. 2020;382(21):2049-55.
6. AMA code of medical ethics: guidance in a pandemic. 2020. https://www.ama-assn.org/delivering-care/ethics/ama-code-medical-ethics-guidance-pandemic [accessed May 7, 2020].
7. National Institute for Health Care Excellence. COVID-19 rapid guideline (NG159): a critical care in adults. NICE guideline 2020. Published March 20, 2020. Last updated April 29, 2020.
8. Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020;369:m1432.
9. Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5 June 2020. https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf [accessed July 15, 2020].
10. Horby P, Lim WS, Emberson J, et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. MedRxiv. 2020. https://www.medrxiv.org/content/10.1101/2020.06.22.20137273v1.full.pdf [accessed July 15, 2020].
11. Guidance for NIH-funded clinical trials and human subjects studies affected by COVID-19. 2020. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-087.html [accessed May 7, 2020].
12. FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency. Guidance for Industry, Investigators, and Institutional Review Boards. Published March 2020. Updated April 16, 2020.